title: [New molecular-targeted agents for colorectal cancer - regorafenib and aflibercept].
abstract: Since the approval of bevacizumab, cetuximab, and panitumumab, development of novel molecular-targeted agents for colorectal cancer has been awaited. Recent phase III trials revealed that new molecular-target agents, regorafenib and aflibercept, are useful for previously treated mCRC. Regorafenib is an oral multi-kinase inhibitor which targets angiogenic, stromal and oncogenic receptor tyrosine kinase(RTK). Aflibercept is a recombinant fusion protein that consists of vascular endothelial growth factor(VEGF)-binding portions from the extracellular domains of human VEGF receptors 1 and 2, fused to the Fc portion of the human IgG1 immunoglobulin. They are different in structure, but an anti-angiogenic effect is one of the main mechanisms of action they have in common. Consistent with the 18147ML study, bevacizumab beyond progression (BBP), anti-angiogenic therapies are important in any line of chemotherapy for colorectal cancer.
authors.affiliation: Dept. of Clinical Oncology, Tohoku University, Japan.
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Kato
mesh_terms: D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D006801:Humans; D058990:Molecular Targeted Therapy; D010671:Phenylurea Compounds / Q000737:chemistry / Q000627:therapeutic use*; D011725:Pyridines / Q000737:chemistry / Q000627:therapeutic use*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000737:chemistry / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000737:chemistry / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D011725:Pyridines; D011993:Recombinant Fusion Proteins; C533178:aflibercept; C559147:regorafenib; D040262:Receptors, Vascular Endothelial Growth Factor